Skip to main content
. 2016 May 20;52(2):599–615. doi: 10.1111/1475-6773.12505

Table 3.

Within‐Participant Investment Level Changes from before Deliberation to after Deliberation for Each Priority, n (%)

Priority Investment Level Change as “Postdeliberation Minus Predeliberation” Changeb (p‐value)
Lower Level at Postdeliberation Higher Level at Postdeliberation
−3 −2 −1 0a 1 2 3
Causes of Disease 9 (5.4) 13 (7.8) 25 (15.0) 75 (44.9) 23 (13.8) 17 (10.2) 5 (3.0) −.04 (.73)
New approaches 11 (6.6) 23 (13.8) 38 (22.8) 54 (32.3) 21 (12.6) 10 (6.0) 10 (6.0) −.28 (.05)
Promote Health 2 (1.2) 12 (7.2) 29 (17.4) 75 (44.9) 30 (18.0) 17 (10.2) 2 (1.2) .07 (.45)
Compare Approaches 2 (1.2) 10 (6.0) 25 (15.0) 74 (44.3) 39 (23.4) 10 (6.0) 7 (4.2) .17 (.06)
Patient‐Doctor 3 (1.8) 11 (6.6) 21 (12.6) 71 (42.5) 44 (26.4) 14 (8.4) 3 (1.8) .17 (.05)
Quality of Life 8 (4.8) 11 (6.6) 28 (16.8) 79 (47.2) 25 (15.0) 7 (4.2) 9 (5.4) −.05 (.60)
Health Inequity 7 (4.2) 15 (9.0) 20 (12.0) 71 (42.5) 35 (21.0) 14 (8.4) 5 (3.0) .04 (.72)
Multiple Conditions 9 (4.8) 16 (9.6) 32 (19.2) 65 (38.9) 26 (15.6) 14 (8.4) 6 (3.6) −.10 (.37)
Special Needs 3 (1.8) 9 (5.4) 31 (18.6) 64 (38.3) 37 (22.2) 16 (9.6) 7 (4.2) .19 (.07)
Families/Caregivers 6 (3.6) 9 (5.4) 21 (12.6) 64 (38.3) 36 (21.6) 17 (10.2) 14 (8.4) .33 (.03)
Access 6 (3.6) 9 (5.4) 28 (16.8) 59 (35.3) 28 (16.8) 17 (10.2) 20 (12.0) .35 (.01)
Improve Research 7 (4.2) 13 (7.8) 27 (16.2) 64 (38.3) 40 (24.0) 7 (4.2) 9 (5.4) .04 (.68)
Rare Diseases 5 (3.0) 12 (7.2) 19 (11.4) 69 (41.3) 40 (24.0) 19 (11.4) 3 (1.8) .17 (.07)
a

Includes those who did not select the priority at both rounds.

b

Mean change in the investment level, where the change is calculated as after deliberation level minus before deliberation level; positive values correspond to higher investment level selection after deliberation, and p‐values are adjusted for within‐CHAT group clustering using multilevel regression model.